Regeneron Pharmaceuticals
REGN · What the business does, what can go wrong, and how options sellers approach it
What it does
Regeneron is a biotechnology company that discovers, develops and sells medicines. Its focus areas include eye disease, allergic and inflammatory conditions, cardiovascular disease and cancer. Many of its drugs are antibodies, engineered proteins that target specific molecules.
It also partners with other drugmakers on newer approaches such as RNA interference and gene editing.
How it makes money
Regeneron earns revenue from selling its own medicines, including treatments for retinal eye disease and a cancer immunotherapy. It also earns collaboration income, mainly from its long-running partnership with Sanofi on Dupixent, a drug for several inflammatory conditions. Under that deal the partners share profits. Regeneron also receives payments tied to partners' sales of other products, such as Eylea outside the U.S.
Why investors own it
- A research engine that has produced several major drugs rather than relying on outside acquisitions.
- Exposure to large markets: eye disease, immunology and oncology.
- A pipeline of experimental drugs that could add new revenue streams.
- Membership in broad indexes like the S&P 500 and Nasdaq-100, so many funds hold it.
What can go wrong
- Biosimilar competition: lower-cost copies of Eylea can erode sales of an important product.
- Concentration: a large share of profit depends on a few drugs, especially Dupixent.
- Clinical and regulatory risk: trials can fail and regulators can delay or reject approvals.
- Partner dependence: results depend partly on how well collaborators market shared products.
- Pricing pressure: government and insurer actions on drug prices can reduce revenue.
What to watch
- Dupixent growth and new approved uses
- Eylea HD uptake versus competing eye treatments
- Clinical trial readouts and FDA decisions
- Progress of pipeline programs in oncology and immunology
- Biosimilar entry and its effect on legacy products
- Drug pricing and reimbursement policy changes
Options income angle
Options on REGN are generally liquid across multiple expirations, though spreads can be wider than on the largest stocks.
Implied volatility tends to rise ahead of earnings, trial results and FDA decisions, then fall once the news is out.
One caution for premium sellers: biotech news can cause sudden price gaps. A failed trial or regulatory setback can move the stock sharply past a short strike. Assignment can also tie up significant capital, depending on the share price at the time.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 4, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
Regeneron's 2025 revenues were $14,342.9 million, little changed from $14,202.0 million in 2024, as a fall in U.S. sales of EYLEA (an eye drug) was offset by growth in profit share from Dupixent, which the company develops with Sanofi. The filing describes a company leaning harder on Dupixent and the newer EYLEA HD while biosimilars (copycat versions of biologic drugs) erode EYLEA.
How the business did
- Net income was $4,504.9 million versus $4,412.6 million, and diluted earnings per share were $41.48 versus $38.34. Income from operations fell to $3,577.9 million from $3,990.7 million. Other income rose to $1,652.8 million from $789.2 million, helped by $946.1 million of gains on marketable and other securities.
- U.S. EYLEA net sales were $2,747.8 million versus $4,767.1 million, which management attributes to competition, patients shifting to compounded bevacizumab (a cheaper off-label alternative) because of affordability, the move to EYLEA HD, and lower prices. U.S. EYLEA HD sales rose to $1,636.9 million from $1,201.1 million.
- Sanofi collaboration revenue was $5,884.0 million versus $4,531.4 million, driven mainly by higher Dupixent sales. Libtayo global net sales were $1,452.2 million versus $1,216.8 million.
- Operating cash flow was $4,978.9 million. Financing activities used $3,715.4 million. The board declared quarterly dividends of $0.88 per share in 2025, and $1.486 billion remained under the share repurchase authorization. Gross margin on product sales slipped to 82% from 86%.
Risks specific to this company
- Concentration: U.S. EYLEA HD and EYLEA were 31% of total revenues and Sanofi collaboration revenue was 41%. Two distributor customers made up 77% of total gross product revenue.
- Biosimilars: U.S. regulatory exclusivity for EYLEA ended in May 2024, and Amgen's Pavblu launched in the fourth quarter of 2024. More biosimilars are expected in the second half of 2026. EYLEA HD has no regulatory exclusivity and depends on patents alone.
- Partners: Regeneron has sued Sanofi, alleging breach of the Dupixent collaboration agreement, and says the effect on the relationship is unknown. Bayer can end the EYLEA collaboration on six or twelve months' notice.
- Manufacturing and FDA: The FDA issued complete response letters (a refusal to approve for now) in July 2025 for odronextamab and in October 2025 for the EYLEA HD pre-filled syringe, tied to inspection findings at third-party fill/finish manufacturers. Regeneron relies entirely on outside parties for filling and finishing.
- Pricing and legal: The filing cites most-favored-nation pricing orders, Medicare price negotiation rules, and civil proceedings brought or joined by the U.S. Department of Justice.
- Debt: Indebtedness was $2.706 billion. The $720.0 million Tarrytown lease financing matures in March 2027.
What management is watching
- Profits and cash flow over the next several years depend on commercializing products including EYLEA HD and Dupixent, along with approval of the EYLEA HD pre-filled syringe.
- Capital spending is expected to be $1.100 billion to $1.300 billion in 2026, for expansion in Tarrytown and a Saratoga Springs property for production support and added manufacturing capacity.
- Research and development expense was $5,850.2 million, and about 45 product candidates are in clinical development.
- Management committed to matching donations for up to a total of $200 million during 2026 to a patient assistance fund for retinal disease copays.
- Management points investors to its share of collaboration profits from Sanofi and Bayer. Contingent reimbursement obligations to them were approximately $595 million and approximately $296 million, and these will be repaid out of that profit share.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed October 30, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
Revenues were $5,115.8 million for the quarter, up from $3,754.3 million a year earlier, mostly because Regeneron's share of Dupixent profits grew. Declining sales of the older EYLEA offset part of that growth. The report also covers an October 2026 expansion of the Sanofi collaboration and new pricing and tariff arrangements with the U.S. government.
How the business did
- Net income was $1,948.7 million, or $18.45 per diluted share, versus $1,460.0 million, or $13.62, a year earlier. For nine months, revenues were $13,011.9 million and net income was $3,972.8 million, versus $10,458.6 million and $3,660.3 million.
- Sanofi records Dupixent sales and Regeneron books its share of the profits as collaboration revenue. Sanofi collaboration revenue was $2,724.0 million, versus $1,617.0 million. Regeneron's share of profits was 38% of Dupixent and Kevzara net sales, versus 29%. Total Dupixent sales were $6,540.5 million, up 35%. The filing also credits full repayment of a development balance owed to Sanofi.
- EYLEA HD sales were $1,082.8 million, up 63%, while EYLEA fell 49% to $658.4 million on biosimilar competition and patients moving to EYLEA HD. Bayer collaboration revenue fell to $266.8 million from $344.8 million. Libtayo sales rose 51% to $550.0 million.
- Gross margin on product sales for nine months was 79%, versus 82%, because a temporary production interruption at the Limerick, Ireland plant left manufacturing costs unabsorbed. Production was back to normal by June 30, 2026, and no product supply was affected.
- Operating cash flow for nine months was $3,675.3 million, versus $3,808.2 million. Cash and marketable securities totaled $18,858.5 million. The company declared a $0.94 quarterly dividend, and $2.157 billion remained under its buyback authorization.
What management is watching
- Management says profits and cash flow over the next several years depend heavily on EYLEA HD and Dupixent. It expects substantial research and commercialization spending and capital expenditures of $1.050 billion to $1.100 billion for 2026.
- In October 2026 Sanofi paid an up-front $1.0 billion, to be booked as collaboration revenue in the fourth quarter, for four added antibodies. Up to $7.0 billion more is possible on milestones.
- Near-term catalysts include a possible FDA approval of the EYLEA HD pre-filled syringe by the end of 2026, an FDA decision on cemdisiran for myasthenia gravis in November 2026, and an odronextamab decision in February 2027.
- Management points investors to its table of net sales for Regeneron-discovered products, including those booked by partners.
New or changed risks
- Pricing agreements: The April 2026 U.S. Government Agreements commit certain products to Most-Favored-Nation Pricing in Medicaid and for future medicines. The filing says they will likely reduce prices and reimbursement for some products.
- Tariffs: New Section 232 pharmaceutical tariffs apply, but the company is exempt through January 2029 if it keeps its U.S. investment commitments. Section 301 tariffs of 10% or 12.5% took effect July 24, 2026. Further investigations could add more.
- Litigation: A putative securities class action was filed in July 2026 against the company and certain employees.
- Patents and pipeline: In March 2026 the patent office opened a post-grant review of an EYLEA HD patent. A May 2026 fianlimab melanoma trial missed its primary endpoint.
Follow REGN in Kortex
The Kortex app shows REGN's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.